ANI Pharmaceuticals vs Harmony Biosciences Holdings
ANI Pharmaceuticals and Harmony Biosciences Holdings are similar in size: $883m and $868m of revenue in their latest fiscal years. ANI Pharmaceuticals grew faster (43.8% against 21.5%). Harmony Biosciences Holdings kept more of each dollar of sales as profit: a net margin of 18.3% against 8.9%.
| Latest fiscal year | ANI PharmaceuticalsANIP, 2025 | Harmony Biosciences HoldingsHRMY, 2025 |
|---|---|---|
| Revenue | $883m | $868m |
| Revenue growth | 43.8% | 21.5% |
| Net income | $78.3m | $159m |
| Operating margin | — | 24.0% |
| Net margin | 8.9% | 18.3% |
| Return on equity | 16.6% | 20.8% |
| Free cash flow | $171m | $348m |
| Cash | $286m | $753m |
| Total debt | $309m | $165m |
| Debt to equity | — | 19.0% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | $12.2m | — |
| Employees | 970 | 293 |
| Market value | $1.61bn | $2.14bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 45 (Weak) | 93 (Strong) |
| Insider trades, 12 months | 0 buys, 50 sales | 0 buys, 13 sales |